×
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
https://ascopost.com/videos/asco20-virtual-scientific-program/richard-schilsky-on-this-year-s-practice-changing-findings/

May 29th, 2020 - Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at the ASCO20 Virtual Scientific Program, including the use of targeted and immunotherapies in earlier lines of therapy, where they have made a significant impact.

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-hofman-on-lupsma-vs-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer/

May 29th, 2020 - Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
https://ascopost.com/videos/asco20-virtual-scientific-program/david-wise-on-novel-biomarkers-in-prostate-cancer/

May 29th, 2020 - David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (A...

Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
https://ascopost.com/news/may-2020/is-sentinel-lymph-node-biopsy-alone-oncologically-safe-for-patients-with-early-stage-cervical-cancer/

May 29th, 2020 - In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node biopsy alone was a valid standard of care, or if bilateral pelvic lymphadenectomy—the current “gold ...

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
https://ascopost.com/videos/asco20-virtual-scientific-program/scott-kopetz-on-encorafenib-plus-cetuximab-with-or-without-binimetinib-in-colorectal-cancer/

May 29th, 2020 - Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).

David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds
https://ascopost.com/videos/asco20-virtual-scientific-program/david-fajgenbaum-on-chasing-his-cure-for-castleman-disease/

May 29th, 2020 - David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.

Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
https://ascopost.com/videos/asco20-virtual-scientific-program/a-message-from-asco-president-howard-burris/

May 29th, 2020 - Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.